## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.1% below STRENGTH zone (4.0-10.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (53% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($244.59)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Dir Farrell Sells 2,000 ($502.9K) Of ResMed Inc [RMD]**
- Source: TradingView | 20251205T000848 | Somewhat-Bearish | Relevance: 100%
- Dir Peter C. Farrell, a Director of ResMed Inc (RMD), filed a Form 4 on December 4, 2025, disclosing a planned sale of 2,000 shares of the company's stock. The transaction, executed pursuant to a 10b5-1 trading plan, resulted in a value of $502,940 at a price of $251.47 per share, leaving his direct holdings at 68,773 shares.

**2. ResMed director Farrell sells $502k in stock**
- Source: Investing.com | 20251204T190820 | Neutral | Relevance: 100%
- ResMed Inc. Director Peter C. Farrell sold 2,000 shares of company stock for $502,940 on December 3, 2025, under a pre-arranged trading plan. Following this transaction, Farrell directly owns 68,773 shares. This sale comes as ResMed recently reported strong Q4 2025 revenue of $1.35 billion, exceeding analyst expectations, although the stock saw a slight pre-market decrease.

**3. 1832 Asset Management L.P. Grows Position in ResMed Inc. $RMD**
- Source: MarketBeat | 20251205T082817 | Somewhat-Bullish | Relevance: 100%
- 1832 Asset Management L.P. significantly increased its stake in ResMed Inc. (NYSE:RMD) by 55.1% during the second quarter, bringing its total holdings to 39,509 shares valued at $10.19 million. Other institutional investors also adjusted their positions in the medical equipment provider. Insiders at ResMed, including CEO Michael J. Farrell and General Counsel Michael J. Rider, recently sold shares, while analysts maintain a "Moderate Buy" rating for the stock with an average target price of $297.45.

**4. ResMed director Farrell sells $502k in stock By Investing.com**
- Source: Investing.com UK | 20251204T190940 | Neutral | Relevance: 100%
- ResMed Inc. Director Peter C. Farrell sold 2,000 shares of company stock for over $502,000, executed under a pre-arranged trading plan. This sale leaves Farrell with 68,773 shares directly owned. The transaction followed ResMed's Q4 2025 earnings report, which exceeded revenue expectations despite a slight stock decrease.

**5. ResMed Inc Reports Changes in CHESS Depositary Interests and Securities**
- Source: MSN | 20251204T151022 | Neutral | Relevance: 100%
- This article from MSN reports on ResMed Inc.'s changes in its CHESS Depositary Interests and securities.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +1.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Forward P/E 21.3x stretched relative to 10% growth. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.7B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 21.3 |
| Current P/E | 23.5 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.4% to 0.1% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. MACD histogram positive (1.30), confirming momentum. RSI neutral at 55. Volume at 53% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.14% (CS: 54) | Neutral |
| RSI_14 | 54.8 | Neutral |
| MACD Histogram | 1.30 | Bullish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 1.015x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $256.55
- **Stop Loss:** $244.59 (4.7% risk)
- **Target:** $268.51 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 41
- **Position Value:** $10,518.55
- **Portfolio %:** 10.52%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*